KR100504767B1 - A functional food Containing herbes composition for allergy disease treatment - Google Patents

A functional food Containing herbes composition for allergy disease treatment Download PDF

Info

Publication number
KR100504767B1
KR100504767B1 KR10-2003-0068445A KR20030068445A KR100504767B1 KR 100504767 B1 KR100504767 B1 KR 100504767B1 KR 20030068445 A KR20030068445 A KR 20030068445A KR 100504767 B1 KR100504767 B1 KR 100504767B1
Authority
KR
South Korea
Prior art keywords
present
functional food
allergic disease
food
allergic
Prior art date
Application number
KR10-2003-0068445A
Other languages
Korean (ko)
Other versions
KR20040030370A (en
Inventor
김경렬
김상태
강형원
Original Assignee
김경렬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020020060006A external-priority patent/KR20030007243A/en
Priority claimed from KR1020020068267A external-priority patent/KR20020089275A/en
Application filed by 김경렬 filed Critical 김경렬
Publication of KR20040030370A publication Critical patent/KR20040030370A/en
Application granted granted Critical
Publication of KR100504767B1 publication Critical patent/KR100504767B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994Coix (Job's tears)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/346Platycodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/60Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605Morus (mulberry)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/78Saururaceae (Lizard's-tail family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 알레르기성 질환 증상의 개선활성을 갖는 기능성 식품에 관한 것으로써, 더욱 상세하게는 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려의 생약을 주성분으로 함유하는 알레르기성 질환 증상의 개선활성 기능을 갖는 기능성 식품에 관한 것이다.The present invention relates to a functional food having an allergic disease symptom improving activity, and more particularly, Euiin, baekbaekpi, Eoseongcho, Giltyeong, raw yellow sulfur, gold and silver, triticale, ginger, dermis, baekchul, creation, Astragalus, licorice, mint The present invention relates to a functional food having an active function of improving allergic disease symptoms containing as a main ingredient herbal medicines such as red pepper, leek, jujube and jujube.

본 발명에 따른 알레르기성 질환 증상의 개선활성 기능을 갖는 기능성 식품은 원인과 체질을 불문하고 사용할 수 있으며, 장기간 계속 사용하더라도 소화장애, 어지러움증 및 속쓰림 등의 부작용이 없는 특징을 갖는다.Functional food having an active function to improve the symptoms of allergic diseases according to the present invention can be used regardless of the cause and constitution, and even without prolonged use, it has the characteristics that there are no side effects such as digestive disorder, dizziness and heartburn.

Description

알레르기성 질환 증상의 개선 기능을 갖는 생약조성물을 함유하는 기능성 식품{A functional food Containing herbes composition for allergy disease treatment} A functional food containing herb composition for improving allergic disease symptoms

본 발명은 알레르기성 질환 증상의 개선 기능을 갖는 식품첨가물 및 상기 식품첨가물을 함유하는 기능성 식품에 관한 것으로, 더욱 상세하게는 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려의 생약을 주성분으로 함유하며, 한의학적인 진단방법에 따른 체질과 변증에 관계없이 알레르기성 질환 증상을 개선시킬 수 있는 기능을 갖는 식품첨가물 및 상기 식품첨가물을 함유하는 기능성 식품에 관한 것이다.The present invention relates to a food additive having an allergic disease symptom improving function and a functional food containing the food additive, and more particularly, Euiin, baekbaekpi, eoseongcho, Gilgyeong, raw yellow sulfur, gold silver, triticale, ginger, dermis, baekchul It is a food additive that has the function of improving allergic disease symptoms regardless of constitution and symptom according to the Chinese medicine diagnostic method as a main ingredient, creation, Astragalus, licorice, peppermint, red pepper, green onion, jujube and herbal medicine And it relates to a functional food containing the food additive.

일반적으로 알레르기 질환의 치료는 약물요법을 이용하는데 항히스타민제, 항생제 또는 호르몬제 등 화학약품이 주로 사용되고 있으며, 상기와 같은 치료제를 복용할 때 그 독성으로 말미암아 소화장애, 어지러움증 및 속쓰림 등의 부작용이 나타나고, 장기 복용시 알레르기 항원에 대한 내성을 가짐으로써 알레르기 증상이 만성화될 수 있는 문제점이 있어 왔다.In general, the treatment of allergic diseases is mainly used for the treatment of drugs such as antihistamines, antibiotics or hormones, and when taking the above-mentioned treatments, side effects such as digestive disorders, dizziness and heartburn appear due to its toxicity. In addition, there has been a problem that allergic symptoms can become chronic by having resistance to allergens when taken for a long time.

이에 최근 생약재 성분을 이용한 알레르기 질환 치료제의 개발이 시도되어지고 있다.Recently, the development of allergic diseases using herbal ingredients has been attempted.

국내특허등록 제354608호에는 형개연교탕(荊芥連翹湯)을 기본방으로 하고 중이염과 풍열을 다스리는 실증치료약재에 보기제가 가미된 처방으로 급만성의 알레르기성 비염, 천식 및 피부염과 중이염 등의 알레르기 질환을 치료하는 조성물이 개시되어 있으나, 상기의 처방은 반드시 식후에 복용하게 되어 있고, 위장상태를 고려하지 않은 처방으로 변증유형에 따라 풍열이 원인이 아닌 경우에는 효과가 미미하거나 차이가 있을 수밖에 없다.Korean Patent Registration No. 354608 is a prescription of Hyeonggae Yeongyo-tang (荊芥 連 翹 湯) as a base room and a treatment agent to treat otitis media and wind fever, and allergies such as acute allergic rhinitis, asthma, dermatitis and otitis media. Although a composition for treating a disease is disclosed, the above prescription is necessarily taken after a meal, and does not consider gastrointestinal conditions. Depending on the type of dialectic, if the fever is not a cause, the effect may be insignificant or may be different. .

또한 최근 생약재를 이용한 알러지성 질환에 대한 연구를 살펴보면, 그 성과물로서 가미통규탕(加味通窺湯), 황연통성산(黃連通聖散), 가미방풍통성산(加味防風通聖散), 통관산(通關散), 형개연교탕가미(荊芥連翹湯加味) 등의 투여시 본 질환에 대한 유의성이 이미 보고된 바가 있으나 효과가 미미하거나 체질과 변증에 맞취 복용해야 한다는 불편감이 있었다.In addition, the recent research on allergic diseases using herbal medicines shows that Kamitonggyutang, Hwangyeontongseongsan, Kamibangpungtongseongsan, and Kwangwansan (通 關 散), Hyunggaeyeon Gyotangami (荊芥 連 翹 湯加 味), etc. The administration of this disease has been reported significantly, but the effect was insignificant or discomfort to take constitution and symptom.

한편, 한의학에서는 알레르기 질환은 풍한(風寒), 풍열(風熱), 습열(濕熱), 조열(燥熱) 등의 외인(外因), 폐허(肺虛), 비허(脾虛), 신허(腎虛) 등의 내인(內因) 또는 음식노역(飮食勞役), 일광 등의 부내외인(不內外因)의 원인에 의한 것이라 하며, 특히 임상에서는 알레르기 질환은 비기허약(脾氣虛弱)으로 인한 경우가 가장 많아 알레르기 질환과 소화기계와의 연관성에 관한 문헌이 다수 보고되어 있다. 특히 오늘날 알레르기 질환은 오염된 공기 뿐만 아니라 식생활의 문제, 즉, 인스턴트 식품, 패스트푸드, 탄산음료 등의 과잉섭취로 인한 위중불화(胃中不和)와도 밀접한 관계가 있는 것으로 알려져 있다.On the other hand, in oriental medicine, allergic diseases include cold, wind, moist fever, external heat such as diarrhea, ruins, deprivation, and kidney pain. It is said to be caused by internal or external causes such as internal or external labor such as daylight or daylight. In clinical practice, allergic diseases are most often caused by undefined weakness. Many literatures have been reported on the association between allergic diseases and the digestive system. In particular, it is known that allergic diseases are closely related to not only contaminated air but also food problems, that is, gastric fluoride caused by excessive intake of fast foods, fast foods, and carbonated drinks.

또한 한의학상으로 보면, 폐(肺)는 기(氣)를 주관하고 비(脾)는 기(氣)의 흐름을 발생시키는 근원점이 되며 폐(肺)와 비(脾) 두 장기는 기(氣)와 수진(水津)의 두 방면에 있어 서로 밀접한 관계가 있으며 병리상에 있어서도 역시 상호영향을 주고 있다. 즉, 비기(脾氣)가 허약하면 폐기(肺氣) 부족에 이르러 폐(肺)의 선항(宣降)작용이 실조(失調)되어 진액(津液)이 정체하므로 한습(寒濕)이 비구(鼻口)에 오랫동안 응결되어 알레르기성 비염이 발생하게 된다. 또한 폐와 장은 장부상합의 음양, 표리의 상응관계로 "폐는 대장과 짝이 되고, 장은 피부와 상응한다(영추, 본장편)"고 하여 소화기관의 문제와도 밀접한 연관이 있다.In addition, in Korean medicine, the lungs control the qi and the nasal cavities are the origin of the flow of the qi, and both the lungs and the nasal organs are qi. ) And Sujin are closely related to each other, and their pathology is also affected. In other words, if weakness is weak, it leads to a lack of disposal, which leads to aberrant action of the lungs and stagnation of fluid. Condensation occurs for a long time, causing allergic rhinitis. In addition, the lungs and the intestines are related to the yin and yang of the upper and lower limbs, "the lungs are paired with the large intestine, and the intestines correspond to the skin (youngchu, this chapter)" is closely related to the problems of the digestive system.

알레르기성 질환은 여러 알레르기 유발인자에 의해 인체 면역체계를 과도하게 항진시켜 대식세포와 같은 면역세포에서 TNF-α(tumor necrosis factor-α), IL-1(interleukin-1), IL-6(interleukin-6), 프로스타글란딘(prostagladin), 루코트리엔(luecotriene) 및 산화질소(nitric oxide, NO)와 같은 염증유발물질을 과도하게 유도하여 염증반응으로 진행되어 알레르기성 비염, 아토피성 피부염, 만성 천식 및 면역 과민반응 증상 등을 일으키는 것으로 알려져 있다.Allergic diseases are caused by excessive allergens in the body's immune system, causing tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) in immune cells such as macrophages. 6) excessively induces inflammatory substances, such as prostaglandin, luecotriene and nitric oxide (NO), leading to inflammatory reactions resulting in allergic rhinitis, atopic dermatitis, chronic asthma And immune hypersensitivity symptoms are known.

그러므로 본 발명은 생약재를 배합하여 한의학상 원인과 체질을 불문하고 알레르기 질환의 증상을 개선할 수 있는 기능성 소재의 개발과 이를 각종 식품에 첨가하는 기능성 식품를 개발 제공하는데 있다.Therefore, the present invention is to provide a development of a functional food that can improve the symptoms of allergic diseases regardless of the cause and constitution of herbal medicines by combining herbal medicines and to develop functional foods added to various foods.

이에 본 발명자들은 각각 장(腸)과 폐(肺)를 튼튼하게 하는 의이인, 상백피, 어성초, 길경; 비위를 돕고 장을 도우며 기를 잘 돌게하는 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작; 및 파, 대추 및 모려의 생약을 주성분으로 함유하는 식품첨가물이 폐(肺), 비(脾), 신(腎), 위(胃), 대장(大腸)에 작용하여 원인과 체질을 불문하고 LPS로 자극 받은 세포주에서 NO의 생산, PGE2의 생산, TNF의 생산 및 전사인자 NF-κB의 활성화를 억제하는 효과가 있음을 동물실험을 통하여 확인하고 본 발명을 완성하였다. The present inventors are the right to strengthen the intestine (폐) and lung (각각), Sangbaekpi, Eoseongcho, Gilgyeong; Raw turmeric, gold and silver, three hundred seconds, ginger, dermis, whiteness, creation, astragalus, licorice, peppermint, antagonism to help stomach and stomach And food additives containing herbal medicines of leek, jujube and soybeans as main ingredients on lung, nasal, renal, stomach, large intestine, and large intestine, regardless of the cause and constitution In animal experiments, it was confirmed that there is an effect of inhibiting NO production, PGE2 production, TNF production, and transcription factor NF-κB activation in cell lines stimulated with.

본 발명은 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a functional food to have an allergic disease symptom.

또한 본 발명은 한의학상 원인과 체질을 불문하고 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a functional food that has an improvement in allergic disease symptoms regardless of the cause and constitution.

아울러 본 발명은 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려의 생약을 주성분으로 함유하는 생약조성물을 이용함으로써, 폐(肺), 비(脾), 신(腎), 위(胃), 대장(大腸)에 작용하여 장기간 계속 사용하더라도 소화장애, 어지러움증 및 속쓰림 등의 부작용을 나타내지 않는 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제공하는 것을 목적으로 한다. In addition, the present invention uses a herbal composition containing Euiin, baekbaekpi, Eoseongcho, Gilgyeong, raw sulfur, gold and silver, three hundred seconds, ginger, dermis, baekchul, creation, Astragalus, licorice, mint, red pepper, green onion, jujube and medicinal herbs as main components This is an allergic disease symptom that does not show side effects such as digestive disorders, dizziness and heartburn, even if it continues to be used for a long time by acting on the lungs, rain, kidneys, kidneys, stomach, and large intestine. An object of the present invention is to provide a functional food that has an improvement function.

상기와 같은 목적을 달성하기 위해서 본 발명은 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려의 생약을 주성분으로 함유하는 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제공한다.In order to achieve the above object, the present invention is the main ingredients of Euiin, Sangbaekpi, Eoseongcho, Gilgyeong, Saenghwanghwang, Geumgeunhwa, three hundred seconds, ginger, dermis, Baekchul, creation, Astragalus, licorice, peppermint, red pepper, green onion, jujube and the main medicine Provides a functional food to have the function of improving the symptoms of allergic diseases containing.

또한 본 발명은 한의학상 원인과 체질을 불문하고 사용할 수 있는 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제공한다.In another aspect, the present invention provides a functional food to have an improvement in allergic disease symptoms that can be used regardless of the cause and constitution.

아울러 본 발명은 폐(肺), 비(脾), 신(腎), 위(胃), 대장(大腸)에 작용하여 장기간 계속 사용하더라도 소화장애, 어지러움증 및 속쓰림 등의 부작용을 나타내지 않는 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제공한다.In addition, the present invention is an allergic disease that does not show side effects such as digestive disorders, dizziness, and heartburn, even if it continues to be used for a long time because it acts on the lungs, rain, kidneys, kidneys, stomach, and large intestine. Provide functional foods to improve symptoms.

이와 같은 본 발명을 더욱 상세히 설명하면 다음과 같다.Referring to the present invention in more detail as follows.

본 발명은 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려의 생약을 주성분으로 함유하는 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제공한다.The present invention is an allergic disease symptom that contains Euiin, baekryepi, eoseongcho, Gilyeong, raw sulfur, gold and silver, three hundred seconds, ginger, dermis, baekchul, creation, Astragalus, licorice, peppermint, red pepper, green onion, jujube and seed Provide functional foods with improved function.

본 발명에서 사용되는 생약재 의이인은 청폐(淸肺)작용을 하고, 비(脾)를 도우며, 폐옹(肺癰), 장옹(腸癰)을 치료하는 데 사용하고, 배농(排膿), 소종(消腫)의 효능이 있으며, 수종각기(水腫脚氣)를 치료하는 데 사용한다. 상백피는 폐의 열을 내리고 기침을 멈추며 숨찬 증세를 낫게 하여 기관지염에 쓰이며, 혈압을 내리는 것을 도와준다. 어성초는 해독작용이 뛰어나며 소염작용을 하고 장의 기능을 활발하게 해주며 피를 맑게 해준다. 길경은 폐경에 작용하여 담을 삭이고 기침을 멈추며 폐기를 잘 통하게 한다. 생지황은 해독작용을 하고 장을 녹여주며 출혈을 멈추게 하며 열을 내린다. 금은화는 청열 및 해독작용을 하고 염증을 삭이고 종기의 고름을 배출시키는 작용을 한다. 삼백초는 해독 및 이뇨작용이 매우 뛰어나고 염증을 없애며 항암작용이 있고, 변비와 숙변을 없애주고 고혈압과 동맥경화 치료와 예방에 사용한다. 생강은 신진대사기능을 촉진하며 진해작용을 하고 위를 보하며 소화를 돕고, 멀미에 약효가 좋으며 혈중 콜레스테롤의 상승을 억제한다. 진피는 비장과 폐에 작용하고 기의 순환을 도와 식용부진, 구토, 기침 등을 다스린다. 백출은 비위를 든든하게 하여 먹은 것을 작 삭이고 기를 보하며 담을 멈춘다. 창출은 습을 없애며 비증을 낫게하고 위를 고르게 하여 먹은 것을 잘 삭인다. 황기는 강장, 지한(止汗), 이뇨(利尿), 소종(消腫) 등의 효능이 있어 신체허약, 피로권태, 기혈허탈(氣血虛脫), 탈항(脫肛), 자궁탈, 내장하수, 식은땀 등에 약효가 좋다. 감초는 비위를 보하고 원기를 도우며, 윤폐, 청열, 해독, 제약을 조화시키는 효능이 있다. 박하는 소산풍열, 청리인후의 효능이 있다. 적작은 활혈산어(活血散瘀), 혈열망행(血熱妄行), 경폐(經閉), 창옹종독(瘡癰腫毒) 등 기어혈제(氣瘀血劑) 작용을 증강시킨다.Herbal medicine Uiin used in the present invention is used to clean the lungs, to help the nasal secretion, to pulmonary, janggong (腸 癰), drainage, small seed (消腫) has the efficacy, and is used to treat several species (水腫 脚氣). Epithelium is used for bronchitis by lowering the heat of the lungs, stopping coughs, and relieving breathing symptoms, and helps lower blood pressure. Eoseongcho has excellent detoxification, anti-inflammatory action, and the function of the intestines to activate and clear blood. Gilyeong acts on menopause to clear the walls, stop coughing, and allow for good disposal. Saengjihwang detoxification, intestinal melts, stops bleeding and lowers fever. Gold and silver are clear and detoxifying, inflammation and to remove the boil pus. Three hundred seconds is very good detoxification and diuretic, eliminates inflammation, has anticancer activity, eliminates constipation and stool, and is used to treat and prevent hypertension and atherosclerosis. Ginger promotes metabolic functions, acts as an antitussive, protects the stomach, aids in digestion, works well for motion sickness, and suppresses the rise of blood cholesterol. The dermis acts on the spleen and lungs, helping the circulation of the group to fight edible, vomiting, and coughing. Baekchul relieves the stomach and breaks down the food while eating. Creation eliminates moisture, heals the secretions and evens the stomach and eats well. Astragalus is effective in tonic, cold, diuretic and small-species, so it has physical weakness, fatigue boredom, bleeding deprivation, disinfection, uterine drainage, visceral sewage, and cold Good effect on sweat. Licorice helps to nourish, refresh, and harmonize rot, cleansing, detoxification and pharmaceuticals. Peppermint has a dissipative wind fever and Cheongryong throat. Jeokjak enhances the action of gear blood agents, such as active blood fish, blood mania, pulmonary pulmonary disease, and swelling poisoning. .

본 발명은 각각 장(腸)과 폐(肺)를 튼튼하게 하는 의이인, 상백피, 어성초, 길경; 비위를 돕고 장을 도우며 기를 잘 돌게하는 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작; 및 파, 대추 및 모려의 생약을 주성분으로 함유하는 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제조한 것이다.The present invention is yiyipi, Sangbaekpi, Eoseongcho, Gilgyeong, respectively, to strengthen the intestines and lungs; Raw turmeric, gold and silver, three hundred seconds, ginger, dermis, whiteness, creation, astragalus, licorice, peppermint, antagonism to help stomach and stomach And functional foods to have the function of improving the symptoms of allergic diseases containing the herbal medicines of green onions, jujube and chaff as a main component.

본 발명의 생약조성물을 함유하는 식품첨가물은 하기 실시예에서 확인할 수 있는 바와 같이 LPS로 자극 받은 세포주에서 NO의 생산, PGE2의 생산, TNF의 생산 및 전사인자 NF-κB의 활성화를 억제하여 알레르기성 질환과 관련있는 알레르기성 비염, 아토피성 피부염, 만성 천식 및 면역 과민반응 증상 등을 개선할 수 있어 한의학상 원인과 체질을 불문하고 사용될 수 있으며, 아울러 본 발명은 폐(肺), 비(脾), 신(腎), 위(胃), 대장(大腸)에 작용하여 장기간 계속 사용하더라도 소화장애, 어지러움증 및 속쓰림 등의 부작용을 나타내지 않는다.The food additive containing the herbal composition of the present invention is allergic by inhibiting the production of NO, the production of PGE2, the production of TNF and the activation of the transcription factor NF-κB in LPS-stimulated cell lines, as can be seen in the following examples. Allergic rhinitis associated with the disease, atopic dermatitis, chronic asthma and immune hypersensitivity symptoms can be improved, and can be used regardless of the cause and constitution of the Chinese medicine, and the present invention, lung (肺), nasal (脾) , Kidney (,), stomach (대), large intestine (大腸) acts long-term use does not show side effects such as digestive disorders, dizziness and heartburn.

본 발명은 상기 생약재 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려의 생약을 혼합하여 물을 첨가하여 열수추출하거나 알코올 수용액을 첨가하여 추출한 후 감압, 분무 또는 동결 건조하여 추출물을 제조한다. 본 발명에 따른 열수추출은 정제수를 가한 후, 80℃에서 4 시간씩 2회 열수 추출할 수 있으며, 알코올 수용액을 첨가할 때는 알코올 수용액은 5 내지 100% 에탄올 또는 메탄올 중에서 선택하여 사용할 수 있고, 더욱 바람직하게는 70% 에탄올을 사용하는 것이 좋다. 또한 본 발명은 상기 추출물을 감압농축기로 농축한 후, 분무 또는 동결 건조하여 상기 추출물의 분말을 제조할 수 있다.The present invention is the herbal medicine, Euibaekpi, Eumseongcho, Gilseong, Saenggihwang, gold and silver, three hundred seconds, ginger, dermis, baekchul, creation, Astragalus, licorice, peppermint, red pepper, green onion, jujube and medicinal herbs are mixed to add water The extract is prepared by extraction or by adding an aqueous alcohol solution, followed by extraction under reduced pressure, spraying, or lyophilization. Hot water extraction according to the present invention can be extracted twice after 4 hours at 80 ℃ after adding purified water, and when the aqueous solution of alcohol is added, the aqueous alcohol solution can be selected from 5 to 100% ethanol or methanol, and more Preferably 70% ethanol is used. In addition, the present invention can be prepared by concentrating the extract in a vacuum concentrator, and then spraying or freeze-drying to prepare a powder of the extract.

본 발명에 따른 생약 조성물중의 각 성분의 배합비는 그들의 종류에 따라서 여러 가지 설정되는 것이 바람직하지만, 예를들어 다음과 같은 배합비가 바람직하다.Although it is preferable that the compounding ratio of each component in the herbal composition which concerns on this invention is set variously according to their kind, For example, the following compounding ratios are preferable.

본 발명에 따른 생약조성물은 생약재 의이인에 대하여 상백피, 어성초 및 길경은 각각 1 : 0.7~1, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하 및 적작은 각각 1 : 0.1~1 이고, 대파는 1 : 1~10, 대추는 1 : 0.1~1, 모려는 1 : 0.01~0.1이며, 보다 바람직하게는 생약재 의이인에 대하여 상백피는 1 : 1, 어성초, 길경은 각각 1 : 0.75, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초는 각각 1 : 0.5 , 박하는 1 : 0.4, 적작은 1 : 0.2, 대파는 1 : 5, 대추는 1 : 0,4 및 모려는 1 : 0.01이다.Herbal medicine composition according to the present invention is about 1: 4 ~ 1 ~ 0.7 ~ 1, raw kohwang, gold and silver, three hundred seconds, ginger, dermis, baekchul, creation, Astragalus, licorice, peppermint and red tide 1: 0.1 ~ 1, leek is 1: 1-10, jujube is 1: 0.1 ~ 1, soybean is 1: 0.01 ~ 0.1, more preferably for herbal medicine yiyiin is 1: 1, Eoseongcho, Gil-Gyeong are 1: 0.75, raw sulfur, gold and silver, three hundred seconds, ginger, dermis, white, creation, Astragalus, licorice 1: 0.5, mint 1: 0.4, red 1: 0.2, leek 1: 5, jujube 1: 0,4 And molar is 1: 0.01.

아울러 본 발명은 필요에 따라 현삼, 건강, 반하, 연교, 지실, 용안육, 신이, 세신, 창이자, 하수오, 백지, 방풍, 사삼, 황기, 계지, 단삼, 소자, 포공영, 시호, 오배자, 자초, 형개, 곽향에서 선택된 1종 이상의 생약을 첨가하여 제조할 수 있으며, 이들은 생약재 의이인에 대하여 각각 1: 0.1~1 중량비로 혼합될 수 있다.In addition, according to the present invention, the present ginseng, health, half, yeonkyo, jisil, longan meat, god, Sesin, Changza, Shouo, white paper, windbreak, Sasam, Astragalus, Gyeji, Dansam, Soja, Pogongyoung, Shiho, fivefold, self It can be prepared by adding one or more herbal medicines selected from Kwak Hyang, and they can be mixed in a weight ratio of 1: 0.1 to 1, respectively.

본 발명에서 알레르기성 질환 증상의 개선 활성이 기대되는 생약추출물의 유효량은 성인(60kg 체중)에 대해 1일 0.5g 내지 4.0g 이고, 바람직하기로는 1일 1.5g 내지 3.0g이며, 각종 식품에 첨가되는 본 발명의 생약추출물은 총 중량의 5 내지 80 중량%가 적당하며, 바람직하기로는 총 중량의 20 내지 70 중량%가 좋고, 더욱 바람직하게는 40 내지 60 중량%가 좋다.In the present invention, the effective amount of the herbal extract expected to improve the symptoms of allergic diseases is 0.5g to 4.0g per day for adults (60kg body weight), preferably 1.5g to 3.0g per day, added to various foods The herbal extract of the present invention is suitably 5 to 80% by weight of the total weight, preferably 20 to 70% by weight of the total weight is preferred, more preferably 40 to 60% by weight.

그리고 본 발명은 상기에서 얻은 생약 추출물을 통상적인 식품에 첨가하여 통상적으로 알려진 방법에 의하여 각종 식품을 제조할 수 있고, 또한 일반적인 제형으로 제형화 될 수 있다.And the present invention can be prepared by a variety of foods by a conventionally known method by adding the herbal extract obtained in the conventional food, it can also be formulated in a general formulation.

본 발명의 생약추출물은 급성독성 시험 결과 식품으로 사용하기에 적합한 것이다.The herbal extract of the present invention is suitable for use as a food result of acute toxicity test.

이하 본 발명을 제조예 및 실험예에 의하여 상세히 설명한다.Hereinafter, the present invention will be described in detail by production examples and experimental examples.

하기 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 내용이 실시예에 의해 한정되는 것은 아니다.The following examples are intended to illustrate the invention and are not intended to limit the scope of the invention.

제조예 1> 본 발명에 따른 생약추출물의 제조Preparation Example 1 Preparation of Herbal Extracts According to the Present Invention

의이인 150g, 상백피 150g, 어성초 112g, 길경 112g, 생지황 75g, 금은화 75g, 삼백초 75g, 생강 75g, 진피 75g, 백출 75g, 창출 75g, 황기 75g, 감초 75g, 박하 60g, 적작 37g, 대파 800g 및 건대추 50g과 1000℃ 이상에서 12시간 열을 가한 법제 모려분 2g을 혼합하고, 증류수를 가하여 이를 80℃에서 4시간 동안 서서히 가열하여 최종적인 부피가 6,000ml이 되게 한 다음, 이를 감압 농축하여 분무 건조시켜 500g의 분말을 얻었다.Eui-in 150g, 150g of lettuce, 150g, Eoseongcho 112g, Gilgyeong 112g, raw yellow sulfur 75g, gold and silver 75g, triticale 75g, ginger 75g, dermis 75g, white extract 75g, creation 75g, Astragalus 75g, licorice 75g, peppermint 60g, red bean 37g, leek 800g and dried jujube 50 g and 2 g of the legal seed powder heated for 12 hours at 1000 ° C. or more were mixed, and distilled water was added thereto and gradually heated at 80 ° C. for 4 hours to give a final volume of 6,000 ml, which was then concentrated under reduced pressure and spray dried. 500 g of powder were obtained.

제조예 2> 생리 등장액의 제조Preparation Example 2 Preparation of Physiological Isotonic Solution

<제조예 1>에서 제조된 생약분말에 생리식염수 100㎖를 가하고 20% NaOH용액으로 pH 7.0이 되게 한 후, 2시간 정도 4℃ 이하로 보관하여 무기염류를 침강시킨 후 milipore filter(pore size 1.2㎛)로 여과하였으며, 이 여과액을 20ml vial병에 담은 뒤 고압멸균기에 넣고 2기압 120℃, 30분 정도 고압멸균 시켰다.100 ml of physiological saline was added to the herbal powder prepared in <Preparation Example 1>, and the pH was adjusted to pH 7.0 with 20% NaOH solution, and then stored at 4 ° C. or less for 2 hours to settle the inorganic salts, followed by a milipore filter (pore size 1.2). Μm), and the filtrate was put in a 20ml vial bottle and placed in a high-pressure sterilizer and autoclaved at 2 atm 120 ° C for about 30 minutes.

실험예 1> 과산화지질(過酸化脂質)생성 억제작용 평가Experimental Example 1 Evaluation of the inhibitory effect of the production of lipid peroxide

Kiso등의 방법을 응용하여 실시하였는데 즉, trihydroxymethylaminomethane (Tris)-HCl 완충액(緩衝液)(167mM KCl, 74.4mM Tris, pH7.4) 500㎕에 쥐간 마이크로솜 현탁액(20mg of protein/ml) 100㎕, 2mM NADPH 100㎕, 10mM ADP 100㎕ 및 10% N,N-dimethylformamide(DMF) 수용액으로 각 농도로 조정한 검체용액 100㎕을 보태서, 37℃에서 5분간 가온하였다. 그 후, 100μM FeCI3 100㎕을 보태서 37℃에서 20분간 가온하였다. The method was applied to the method of Kiso, that is, 100 μl of rat liver microsome suspension (20mg of protein / ml) in 500 μl of trihydroxymethylaminomethane (Tris) -HCl buffer (167mM KCl, 74.4mM Tris, pH7.4). 100 μl of the sample solution adjusted to each concentration with 100 μl of 2 mM NADPH, 100 μl of 10 mM ADP and 10% N, N-dimethylformamide (DMF) solution was added thereto, and warmed at 37 ° C. for 5 minutes. Then, 100 μl of 100 μM FeCI3 was added and warmed at 37 ° C. for 20 minutes.

콘트롤에는 검체용액 대신에 10% DMF 수용액 100㎕을 보탰으며, 그리고 NADPH 100㎕, FeCI3 100㎕, ADP 100㎕ 대신에 물 300㎕을 보탰다. 빙냉(氷冷)으로 의해 반응을 정지한 후, Ohkawa 등의 방법에 준하여 과산화지질량을 마론디알디히드 (malondialdehyde)양으로서 산출하였다. 즉, 반응액 1㎖에 8.1% sodium dodecyl sulfate(SDS) 수용액 200㎕, 초산완충액(0.27M HCl를 포함한 20% AcOH를 10M NaOH로 pH3.5로 조정하였다.) 1.5ml을 보태서 비등수욕상(沸騰水浴上)에서 20분간 가열하였다. 가열 후 빙냉(氷冷)으로 반을 정지하고 n-BuOH-pyridine혼액(15:1) 4㎖을 보태서 세차게 혼화하였다. For control, 100 μl of 10% DMF solution was added instead of sample solution, and 300 μl of water instead of 100 μl of NADPH, 100 μl of FeCI3, and 100 μl of ADP. After stopping the reaction by ice cooling, the mass of fat peroxide was calculated as the amount of malondialdehyde according to the method of Ohkawa et al. In other words, 200 ml of 8.1% sodium dodecyl sulfate (SDS) aqueous solution and acetic acid buffer solution (adjusted 20% AcOH containing 0.27 M HCl to pH 3.5 with 10 M NaOH) were added to 1 ml of the reaction solution. Heated for 20 minutes. After heating, the mixture was stopped by ice-cooling and the mixture was finely mixed with 4 ml of n-BuOH-pyridine mixture (15: 1).

그 후 800 ×g에서 10분간 원심분리한 후 떠오른 표면액체 532nm에서의 흡광도를 측정하였는데 그 결과는 도 1과 같다. 쥐 간(肝) 마이크로솜을 사용한 ADP/Fe3+ 유발 지질과산화 반응에 대하여 본 발명에 의한 생약 조성물은 농도의존적으로 억제작용을 나타내었으며, 양성대조인 BHT보다도 강력한 저해작용을 나타냄을 볼 수 있다.Thereafter, after centrifugation at 800 x g for 10 minutes, the absorbance at the surface liquid 532 nm was measured, and the results are shown in FIG. 1. The herbal composition according to the present invention exhibited a concentration-dependent inhibitory effect on ADP / Fe3 + induced lipid peroxidation reaction using rat liver microsomes, and showed a stronger inhibitory effect than the positive control BHT.

실험예 2> 쥐 경구투여에서의 항(抗)알레르기 작용(PCA법) 평가Experimental Example 2> Evaluation of antiallergic action (PCA method) in oral administration of rat

경구 항알레르기약 트라니라스트 (tranilast)를 양성 대상으로 하여 쥐의 피부 아나피라키시 (anaphylactic)반응 (PCA반응)을 사용하여 본 발명의 약학 조성물의 항알레르기 작용을 평가하였다. Koda 등의 방법 Int. Arch. Allergy Appl. Immunol. 87, 254(1988)에 준하였다. 체중 약 200g의 Wister계 숫컷쥐 등부위의 털을 깎고, 48시간 homologous PCA 역가(力價)가 1:128-1:256을 표시하는 항혈청을 생리 식염수로 희석하여 그 0.1ml를 등부위에 피내 주사하였다. 48시간 후, 단백량(蛋白量)으로 1mg의 DNP-BSA를 포함한 0.5% Evans blue 생리식염액 1ml을 꼬리정맥에 주사하였다. 30분후, 쥐를 방혈(放血)치사시켜 등부위 피부에 생긴 색소반(色素斑)을 절취하여 누출된 색소량을 구하였다. 즉, 절취한 피부를 시험관에 넣고, 1N KOH 1ml을 보태서, 37℃에서 하룻밤 방치하여 색소를 용출(溶出)시키며, 여기에 아세톤과 0.6N 인산혼액(13:5) 9ml을 보태서 흔들고 불용물(不溶物)을 여과제거한 후, 620nm로 여액의 흡광도를 측정하여 색소량을 측정하였으며 족부부위의 색소침착정도를 확인하였다. 검체는 0.2% CMC - Na로 현탁하며, 쥐 체중 100g당 0.5 ml 투여가 되도록 조정하여 항원투여 2시간전에 경구 투여하였다. The antiallergic action of the pharmaceutical compositions of the present invention was evaluated using the dermal anaphylactic reaction (PCA reaction) of rat oral antiallergic drug tranilast. Koda et al. Int. Arch. Allergy Appl. Immunol. 87, 254 (1988). Shave the back of Wister male rats weighing about 200 grams, dilute antiserum with homologous PCA titers of 1: 128-1: 256 with physiological saline for 48 hours, and inject 0.1ml intradermally into the back. It was. After 48 hours, 1 ml of 0.5% Evans blue saline solution containing 1 mg of DNP-BSA was injected into the tail vein as a protein. After 30 minutes, the rats were bled and cut off the pigmented spots on the skin of the back to determine the amount of leaked pigment. In other words, the cut skin is placed in a test tube, and 1 ml of 1N KOH is added, and the pigment is eluted by leaving it at 37 ° C. overnight, and 9 ml of acetone and 0.6 N phosphate mixture (13: 5) are added to shake and insoluble matter ( After filtering off the filtrate, the absorbance of the filtrate was measured at 620 nm to measure the amount of pigment, and the degree of pigmentation of the foot was confirmed. The samples were suspended in 0.2% CMC-Na, adjusted to 0.5 ml dose per 100 g of rat body weight, and orally administered 2 hours before challenge.

도 2에서 볼 수 있듯이 본 발명에 의한 조성물은 경구투여에서도 항알레르기 활성을 나타내며, 대조군보다도 강한 활성을 나타냈다.As can be seen in Figure 2, the composition according to the present invention showed anti-allergic activity even in oral administration, showed a stronger activity than the control.

실험예 3> 5-리포키시게나제 저해작용 평가Experimental Example 3> Evaluation of 5-lipokishgenase Inhibitory Activity

Blackham등의 방법을 응용하여 실시하였는데 즉, 세포수가 1 ×107cells/ml의 농도가 되도록 50mM 인산완충액으로 조정한 RBL-1 세포부유액을 초음파 처리하여 세포를 파괴하였다. 이 세포 호모지네이트(homogenate)액 500㎕에 1% DMSO로 각 농도로 조정한 검체용액 10㎕, 100mM CaCl2 10㎕ 및 10mg/㎖ 아라기돈(arachidonic)산의 MeOH용액 10㎕을 보태서 37℃에서 3분간 가온하였다. 콘트롤(control)에는 검체대신에 1% DMSO 10㎕를 보탰다. 또한, 불랭크(blank)에는 검체 대신에 1% DMSO 10㎕를 보태고, RBL-1 세포부유액을 대신하여 50mM 인산완충액 500㎕을 보탰다. 그 후, MeOH 500㎕을 보태고 빙냉으로 반응을 정지하고 혼합한 후, 4℃, 2,000 ×g로 15분간 원심 분리하였다. 이어서 하기조건에서 HPLC에 의해 떠오른 표면액체 10㎕중의 5-HETE량을 측정하였다. Blackham et al. Applied the method, namely, the cells were disrupted by sonicating RBL-1 cell suspension adjusted with 50mM phosphate buffer so that the cell number was 1 × 10 7 cells / ml. To 500 µl of this cell homogenate solution, 10 µl of sample solution adjusted to each concentration with 1% DMSO, 10 µl of 100 mM CaCl 2 and 10 µl of Memg solution of 10 mg / ml arachidonic acid were added at 37 ° C. Warm for 3 minutes. Control was given 10 μl of 1% DMSO instead of the sample. In addition, 10 µl of 1% DMSO was added to the blank and 500 µl of 50 mM phosphate buffer was added instead of the RBL-1 cell suspension. Thereafter, 500 µl of MeOH was added, the reaction was stopped by ice-cooling and mixed, and then centrifuged at 4 ° C and 2,000 x g for 15 minutes. Subsequently, the amount of 5-HETE in 10 µl of the surface liquid floated by HPLC was measured under the following conditions.

<HPLC 조건><HPLC condition>

컬 럼; Cosmosil 5C18 (4. 6 x 150mm) column; Cosmosil 5C18 (4.6 x 150mm)

이동상; acetonitrile : 0.1%acetic acid=85 : 15 Mobile phase; acetonitrile: 0.1% acetic acid = 85: 15

유 속 ; 1.0ml/minFlow velocity; 1.0ml / min

검출파장; 235nmDetection wavelength; 235 nm

5-리포키시게나제 활성에 대한 저해율은 하기 수식에 의해 산출하였다. Inhibition rate for 5-lipokishgenase activity was calculated by the following formula.

저해율(%) = ( (검체-블랭크) × 100 ) ÷(대조군-블랭크)=% Inhibition = ((sample-blank) × 100) ÷ (control-blank) =

도 3에서 본 발명의 약학 조성물은 5-리포키시게나제에 대한 저해활성(IC50)이 약 18 pg/㎖이며, 양성대상 화합물 BHT (IC50 = 28 pg/ml)보다도 강한 억제활성을 나타냈다.In FIG. 3, the pharmaceutical composition of the present invention has an inhibitory activity (IC50) of about 18 pg / ml on 5-lipokinase, and showed stronger inhibitory activity than that of the positive compound BHT (IC50 = 28 pg / ml).

실험예 4> 항(抗)히스타민 작용 평가Experimental Example 4> Evaluation of Antihistamine Activity

염산 디펜하이드라민(diphenhydramine)을 양성대조로 한 본 발명의 생약 조성물의 모르모토 양관을 사용하는 마그너스법(magnus)에 의한 항(抗)히스타민 작용을 시험하였다. 하룻밤 절식시킨 모르모트를 박살(撲殺)하고, 회장(回腸)을 적출하여 약 2㎝의 길이로 절취하여 일단을 isotonic transducer에 걸어 놓으며, 타단을 고정봉에 고정시킨다. 항온조(恒溫槽)의 온도를 37℃로 유지하며, 10㎖의 Tyrode액 중에 O2 95%, CO2 5%의 혼합가스를 통기(通氣)하면서 약 30분간 방치한 후, 각 농도의 히스타민을 주입하여 트레이닝 후 세정 하여 검체투여 하에서 똑같이 히스타민에 관한 값을 산출하였다. 그 결과 도 4에 나타낸 바와 같이 본 발명의 약학조성물의 항(抗)히스타민 효과는 대조군에 비해 2배에서 4배정도 이상 강하게 나타났다.The antihistamine action by the Magnus method using the Mormoto tube of the herbal composition of this invention which positively controlled diphenhydramine hydrochloride was tested. The mortar, which has been fasted overnight, is smashed, the ileum is removed, cut to a length of about 2 cm, one end is hanged on the isotonic transducer, and the other end is fixed to the fixed rod. And maintaining the temperature of the constant temperature bath (恒溫槽) in 37 ℃, and then, while breathable (通氣) a mixed gas of O 2 95%, CO 2 5 % in the Tyrode solution of 10㎖ allowed to stand for about 30 minutes, histamine for each concentration Injected, washed and trained, the same values for histamine were calculated under sample administration. As a result, as shown in FIG. 4, the antihistamine effect of the pharmaceutical composition of the present invention was about 2 to 4 times stronger than the control group.

실험예 5> 트라이나이트로페닐(TNP)의 특이적 면역조정능력반응 실험Experimental Example 5> Specific immunomodulatory ability test of trinitrophenyl (TNP)

트라이나이트로벤젠술폰산을 인산완충화생리식염수에 용해하고 (35㎎/7.0㎖, pH 7.5), 여기에 1㎖의 양적혈구 페렛을 섞으면서 떨어뜨렸다. 차광상태에서 여러차례 섞으면서 30분간 실온에 방치한 후, 생리식염수로 2회 세정했다. 3,000 rpm으로 5분간 원심분리한 후, 생리식염수로 5 ×109/㎖로 제조하는데 6주령(週齡)의 암컷 BALB/c 마우스에게 5 × 109개의 TNP-SRBC를 복강내로 투여하고, 혈청중의 항TNP항체를 디니토로페닐 소혈청 알부민(DNP-BSA)을 이용한 효소면역측정법(ELISA)으로 측정했다. 그 결과, 7일째를 피크로 하여 항TNP-IgM 및 항 TNP-IgG의 강한 항체생산이 확인되었다. 더구나 흉선결여(胸腺缺如)된 BALB/c 누드마우스에서는 양쪽 타입의 항체생산은 거의 확인되지 않았다. 상기한 실험계를 이용하여, 생리식염수에 용해한 본 신비전에 대한 히스타민가마우스(加mouse)γ-글로불린 (200㎎/㎏/day)에 있어서, TNP-SRBC 감작일로부터 7일간의 경구투여에 의한 항TNP항체생산에 대한 작용을 조사했다. 또, 양성대조로써 히스타민가마우스γ-글로불린 (200㎎/㎏/day)을 같은 형태로 피하주사하여 비교하였다. 본 실험예에 있어서의 결과를 도 5에 나타냈다. 또, 이하의 실험결과에 있어서는, Student's t-test를 이용하여 대조와의 평균치의 의미있는 차이를 구해 *표시를 했다. (* : p<0.05, ** : p<0.005)Trinitrobenzenesulfonic acid was dissolved in phosphate buffered physiological saline (35 mg / 7.0 mL, pH 7.5) and dropped therein with 1 mL of quantitative blood cell ferret. It was left to stand at room temperature for 30 minutes while mixing several times in a light shielding state, and then washed twice with physiological saline. After centrifugation at 3,000 rpm for 5 minutes, 5 × 109 TNP-SRBCs were intraperitoneally administered to 6-week-old female BALB / c mice to prepare 5 × 109 / ml with saline. Anti-TNP antibodies were measured by enzyme-linked immunoassay (ELISA) using dinitrophenyl bovine serum albumin (DNP-BSA). As a result, strong antibody production of anti-TNP-IgM and anti-TNP-IgG was confirmed as the peak at day 7. In addition, almost no type of antibody production was observed in BALB / c nude mice lacking thymus. Anti-TNP by oral administration for 7 days from the TNP-SRBC sensitized day in histamine gamma-globulin (200 mg / kg / day) for this mysterious war dissolved in physiological saline using the experimental system described above. The effect on antibody production was investigated. In addition, as a positive control, histamine gamma γ-globulin (200 mg / kg / day) was compared by subcutaneous injection in the same form. The result in this experiment example is shown in FIG. In addition, in the following experiment result, the meaningful difference of the mean value with a control was calculated | required by * using the Student's t-test. (*: p <0.05, **: p <0.005)

실험예 6> 호산구 증가 억제작용평가Experimental Example 6 Evaluation of Eosinophil Growth Inhibitory Activity

6주령의 암컷인 BALB/c마우스에, 본 발명에 의한 약학조성물을 1일 30㎎씩 경구투여 하면서 생리식염수로 1,000배 희석한 호그위드 화분액체를 개시일 및 제 1일째에는 100㎕, 다시 100㎕를 7, 14일째에 피하주사하여 감작했다. 제 21일째에 1,000배 희석된 호그위드항원 100㎕를 마우스 복강내에 주사하고 반응을 유발했다. 유발후 24시간째에 복강침출세포를 회수하고, 김자염색으로 총세포수, 호산구수, 호중구수, 단핵세포수를 계측했다. 그 결과, 도 6에 나타낸 바와 같이 대조군에서는 호산구수는 유발후 27일째에 최고로 되었으나 실험군을 50 mg/Kg처리군 경우 27일째 대조군 경우보다 약 4배의 억제효과를 보였다. 더구나, T세포가 결여되어 있는 BALB/c 누드마우스에서는 호산구경우 복강내에의 침윤은 전혀 인지되지 않았다.BALB / c mice, 6-week-old females, were orally administered 30 mg / day of the pharmaceutical composition according to the present invention, and 100 μl of Hogweed pollen fluid diluted 1,000-fold with physiological saline was 100 μl and 100 μl on the first day. Was subcutaneously injected on days 7 and 14. On day 21, 100 μl of 1,000-fold diluted hogweed antigen was injected intraperitoneally into the mouse and the reaction was induced. Peritoneal leached cells were harvested 24 hours after induction, and total cell number, eosinophil count, neutrophil count, and monocyte count were measured by laver staining. As a result, as shown in FIG. 6, the eosinophil count in the control group was the highest on the 27th day after induction, but the experimental group showed about 4 times the inhibitory effect than the control group on the 27th day of the 50 mg / Kg treatment group. Moreover, in BALB / c nude mice lacking T cells, eosinophils did not recognize any intraperitoneal infiltration.

실험예 7> 산화질소(NO) 생성 억제 효능 실험Experimental Example 7> Nitric Oxide (NO) Production Inhibition Effect Experiment

본 발명에 따른 생약 조성물의 알레러기 비염 효능을 검정하기 위해서 비염유발은 Bellofiore 등의 변형에 준해서 각 군당 랫트 5마리씩 두 군을 준비하여, 첫째 날 Ovalbumin(OA) 1mg을 0.9% saline 1ml에 녹여 피하 주사하고, 6×109 B. pertussis bacilli를 포함한 0.9% saline 1ml를 비강내로 주입하여 immunization을 시켰다. 전신적인 immunization후 14일째 랫트들에 2% (wt/vol) OA를 함유한 0.9% saline aerosol을 흡입시킴으로써 항원감작에 의한 알레르기성 비염을 유발시켰다. Aerosol은 ultrasonic nebulizer에 의해 만들어졌고, 20분간 흡입시켰다.In order to assay the allergic rhinitis efficacy of the herbal composition according to the present invention, the rhinitis-induced rhizome was prepared in two groups of 5 rats per group according to the modification of Bellofiore, etc., and dissolved 1 mg of Ovalbumin (OA) in 1 ml of 0.9% saline on the first day. Subcutaneous injection and immunization were performed by intranasal injection of 1 ml of 0.9% saline containing 6 × 10 9 B. pertussis bacilli . Allergic rhinitis by antigen sensitization was induced by inhalation of 0.9% saline aerosol containing 2% (wt / vol) OA in rats 14 days after systemic immunization. Aerosol was made by ultrasonic nebulizer and inhaled for 20 minutes.

비염 유발 24시간 후, <제조예 2>에서 제조한 등장액을 투입시켰다.After 24 hours of rhinitis induction, the isotonic solution prepared in Production Example 2 was added thereto.

상기의 랫트 10마리를 클로로포름으로 마취시킨 다음 심장천자하여 혈액을 EDTA(Ethylene Diamine Tetraaccetic Acid Dipotassium Salt)가 들어 있는 시험관에 넣고 잘 섞어 응고를 방지한 뒤 원심분리기로 3000rpm으로 5분간 원심분리 후 상등액을 NO생성도를 확인하기 위해 96well에 50㎕씩 옮기고 여기에 발색시약인 Griess시약(1% sulphanilamide, 0.1% naphlethyendiamine dihydrochloride, 4% phosphoric acod) 50㎕정도 처리하여 NO생성도를 570nm에서 ELISA reader로 측정하였다.10 rats were anesthetized with chloroform, cardiac punctured, and the blood was poured into a test tube containing EDTA (Ethylene Diamine Tetraaccetic Acid Dipotassium Salt), mixed well to prevent coagulation, and centrifuged at 3000 rpm for 5 minutes using a centrifuge. To confirm NO production, transfer 50µl to 96well and process 50µl of Griess reagent (1% sulphanilamide, 0.1% naphlethyendiamine dihydrochloride, 4% phosphoric acod), which is a color development reagent, and measure NO production at 570nm with ELISA reader. It was.

[표 1] Ovalbumin으로 유발된 비염 랫트들의 NO생성도Table 1 NO Production of Ovalbumin-Induced Rhinitis Rats

시료sample NO생성도(μM/well)NO generation (μM / well) 정상군Normal 4.0±1.824.0 ± 1.82 대조군Control 78.2±2.9*78.2 ± 2.9 * 실험군Experimental group 23.1±3.523.1 ± 3.5

*p<0.05* p <0.05

상기 실험결과 정상군의 NO생성도는 4.0±1.82μM이고, 대조군은 78.2±2.9μM 정도였으며, 본 발명의 조성물의 처리군은 23.1±3.5μM로서, 대조군에 비해 유의한 차이를 나타내었다.As a result, the NO production of the normal group was 4.0 ± 1.82 μM, the control group was about 78.2 ± 2.9 μM, and the treatment group of the composition of the present invention was 23.1 ± 3.5 μM, which showed a significant difference from the control group.

이러한 결과로부터 본 발명에 따른 생약 조성물이 관절염, 패혈증 등의 염증질환과 조직이식거부반응, 자가면역질환, 당뇨병 등의 면역질환 및 신경세포의 사멸을 유발하는 것으로 알려진 염증 유발물질인 산화질소(nitric oxide, NO)의 생성을 억제하는 효과가 있는 나타내는 것을 알 수 있다.From these results, the herbal composition according to the present invention is nitric oxide (nitric), an inflammation-inducing substance known to cause inflammatory diseases such as arthritis, sepsis and tissue transplant rejection, autoimmune diseases, immune diseases such as diabetes, and neuronal cell death. It can be seen that there is an effect that suppresses the production of oxide, NO).

실험예 8> 비염과 기관지의 염증반응실험Experimental Example 8> Inflammatory Response Test of Rhinitis and Bronchus

상기 <실험예 7>에서와 같이 실험동물에 OA aerosol 흡입시킨 후, 다음날에 기관지세척을 시행하였다.After inhaling OA aerosol in the experimental animals as in <Experiment 7>, bronchial washing was performed the next day.

0.1% EDTA 2Na를 포함한 PBS(Phosphate buffered saline; Sodium Chloride 8g, Pottassium Chloride 0.2g, Disodium Hydrogen Phosphate 1.15g, Calcium Chloride 0.0005g, Magnesium Chloride 0.0005g) 4ml를 3번 주입하여 기관지를 세척한 후에 BALF를 얻었다. 부피는 원래 부피의 대략 평균 80%로 전체 세포수는 hemocytometer를 사용해서 측정하였으며 그 결과는 하기 표 2와 같다. 4 ml of PBS (Phosphate buffered saline; Sodium Chloride 8g, Pottassium Chloride 0.2g, Disodium Hydrogen Phosphate 1.15g, Calcium Chloride 0.0005g, Magnesium Chloride 0.0005g) containing 0.1% EDTA 2Na was washed three times before BALF was washed. Got it. The volume was approximately 80% of the original volume and the total cell number was measured using a hemocytometer. The results are shown in Table 2 below.

임파구수는 BALF에 lymphoprep(1.077±0.0001 g/ml, Nycomed PharmaAs, Oslo, Norway)를 첨가하여 25분 동안 2,000 rpm에서 원심 분리한 후 상층을 버리고, 중간에 하얗게 부유해 있는 lymphocyte를 분리한 다음 PBS에 부유시켜 200 ×g에서 10분간 3회 원심 세척한 후, RPMI medium에 부유시키고, 광학 현미경을 이용하여 Trypan blue exclusion으로 세포수를 측정하였으며 그 결과는 도 7 및 8에 나타내었다.Lymphocyte counts were added to lymphoprep (1.077 ± 0.0001 g / ml, Nycomed PharmaAs, Oslo, Norway) in BALF, centrifuged at 2,000 rpm for 25 minutes, discarded the upper layer, and separated white lymphocytes. After centrifuged for 3 minutes at 200 × g for 10 minutes, the cells were suspended in RPMI medium and the number of cells was measured by Trypan blue exclusion using an optical microscope. The results are shown in FIGS. 7 and 8.

[표 2]TABLE 2

시료sample 세포수(×105/㎖)Cell number (× 10 5 / ml) 정상군Normal 6.34±1.256.34 ± 1.25 대조군Control 27.43±1.5327.43 ± 1.53 실험군Experimental group 10.63±0.3410.63 ± 0.34

상기 결과로부터 기관지 세정액 내의 총세포수는 정상군은 6.34±1.25 ×105/㎖이고, 대조군에서는 27.43±1.53 ×105/㎖이었으나, 본 발명의 조성물로 처리한 실험군에서는 10.63±0.34 ×105/㎖이어서 대조군에 비해 유의한 감소효과를 나타냄을 볼 수 있다.From the above results, the total cell count in the bronchial lavage fluid was 6.34 ± 1.25 × 10 5 / ml in the normal group and 27.43 ± 1.53 × 10 5 / ml in the control group, but in the experimental group treated with the composition of the present invention, 10.63 ± 0.34 × 10 5 / Ml can be seen to show a significant reduction compared to the control.

또한 임파구 수는 정상군은 2.23±1.45 ×105/㎖이고 대조군은 14.53±1.01 ×105/㎖이었으나, 본 발명의 조성물로 처리한 실험군에서는 5.71±2.45 ×105/㎖로서 대조군에 비해 약 60% 정도 감소하였음을 볼 수 있다.In addition, lymphocyte number is the normal group was 2.23 ± 1.45 × 10 5 / ㎖ and the control group was approximately as compared with the control group as 14.53 ± 1.01 × 10 yieoteuna 5 / ㎖, the experimental group treated with the composition of the invention 5.71 ± 2.45 × 10 5 / ㎖ It can be seen that the reduction by 60%.

실험예 9> T세포의 CD4+/CD8+ 수적증가 확인Experimental Example 9> Confirmation of Increase of CD4 + / CD8 + Number of T Cells

기도 세척액 내의 T-cell측정을 위해 RPMI 배지에 부유시킨 임파구 세포를 media A(pH 7.2 PBS+ 5% FBS with RPMI + 2M sodium azide)에 2×107 cells/㎖의 세포수를 재부유시키고, 시험관에 세포부유액 50㎕씩 넣어서 시험관마다 1×106개의 세포가 존재하게 하였다. 각 시험관에 FITC Anti-Rat CD4+ Monoclonal Antibody (Cedarlane, Ontario, Canada)와 PE Anti-Rat CD8+ Monoclonal Antibody(Cedarlane, Ontario, Canada)를 각각 0.5㎍씩 가하고, Vortex mixer로 잘 섞은 다음 이 혼합액을 빛이 차단되도록 알루미늄 호일로 씌우고 4℃에서 30분간 배양한 뒤, 4℃에서 PBS로 2회 세척하고, 50㎕의 ice cold media B(pH 7.2 PBS + 0.5% Bovine serum albumin + 2M sodium azide)에서 cell pellet을 재부유시킨 후 형광현미경을 이용하여 임파구에 대한 CD4+ 및 CD8+ T세포율을 측정하였다. 세포수는 산출된 lymphocyte에 CD4+, CD8+의 비율을 곱하여 계산하였다.Lymphocyte cells suspended in RPMI medium for T-cell measurement in airway lavage fluid were resuspended in media A (pH 7.2 PBS + 5% FBS with RPMI + 2M sodium azide) at 2 × 10 7 cells / mL cell count. 50 μl of cell suspension was added to the cells so that 1 × 10 6 cells were present in each test tube. Add 0.5 μg of FITC Anti-Rat CD4 + Monoclonal Antibody (Cedarlane, Ontario, Canada) and PE Anti-Rat CD8 + Monoclonal Antibody (Cedarlane, Ontario, Canada) to each test tube, mix well with Vortex mixer, and mix the mixture with light. Cover with aluminum foil, incubate for 30 minutes at 4 ° C, wash twice with PBS at 4 ° C, and cell pellet in 50ul ice cold media B (pH 7.2 PBS + 0.5% Bovine serum albumin + 2M sodium azide). After resuspending, CD4 + and CD8 + T cell rates for lymphocytes were measured using a fluorescence microscope. The cell number was calculated by multiplying the calculated lymphocytes by the ratio of CD4 + and CD8 +.

[표 3]TABLE 3

시료sample CD4+(×104/㎖)CD4 + (× 10 4 / ml) CD8+(×104/㎖)CD8 + (× 10 4 / ml) 정상군Normal 1.34±0.211.34 ± 0.21 1.12±0.521.12 ± 0.52 대조군Control 6.13±1.536.13 ± 1.53 5.02±0.565.02 ± 0.56 실험군Experimental group 3.65±2.343.65 ± 2.34 1.62±0.751.62 ± 0.75

상기의 실험결과로부터 기도 세정액 내의 CD4+ 임파구 수는 정상군에서는 1.34±0.21 ×104/㎖이고, 대조군에서는 6.13±1.53 ×104/㎖정도였으나, 본 발명의 생약 조성물을 처리한 실험군에서는 3.65±2.34 ×104/㎖로서 대조군에 비해 상당히 Th2에서 유래한 CD4+의 수가 유의한 감소효과를 나타내었으며, CD8+ 임파구 수는 정상군에서는 1.12±0.52 ×104/㎖이고 대조군에서는 5.02±0.56 ×104/㎖정도이었으나, 본 발명의 생약 조성물을 처리한 실험군에서는 1.62±0.75 ×104/㎖로서 대조군에 비해 약 62%정도 감소하는 효과를 나타냄을 알 수 있다.From the above experimental results, the number of CD4 + lymphocytes in airway lavage was 1.34 ± 0.21 × 10 4 / ml in the normal group and 6.13 ± 1.53 × 10 4 / ml in the control group, but 3.65 ± in the experimental group treated with the herbal composition of the present invention. 2.34 × 10 4 / mL significantly reduced the number of CD4 + derived from Th2 compared to the control group, and CD8 + lymphocyte count was 1.12 ± 0.52 × 10 4 / mL in the normal group and 5.02 ± 0.56 × 10 4 in the control group. / Ml, but the experimental group treated with the herbal composition of the present invention is 1.62 ± 0.75 × 10 4 / ㎖ can be seen that the effect of about 62% decrease compared to the control group.

따라서 본 발명에 의한 생약 조성물이 비염유도에 의한 T임파구의 CD4+ 및 CD8+의 증가를 억제하는 데 효과적임을 알 수 있다.Therefore, it can be seen that the herbal composition according to the present invention is effective in suppressing the increase of CD4 + and CD8 + of T lymphocytes caused by non-saline.

실험예 10> 혈액 내 T세포의 감소 유무 확인Experimental Example 10> Confirmation of Reduction of T Cells in Blood

5% RPMI medium에 penicilin/streptomycin이 함유한 배지상에 104 세포를 둥근 유리판(slimb cover glass)가 들어 있는 6 well culture dish에 분주하고 37℃에서 24시간 배양하고, 본 발명의 제조예 1에서 제조된 약학조성물을 50㎍/ml이 되게 첨가하여 반응을 관찰하였으며, 폐액을 제거 한 후 세포를 한번 PBS로 세척한 다음 세포를 metanol로 세포 위에 떨어지게 고정시킨 다음 PBS로 세척을 실시하고 3회 실행한 다음 0.2% BSA(bovine serum albumin)로 blocking후 1차항체인 Anti-mouse-CD4+/CD8+로 2차 항체인 anti-mouse-conjugated된 FITC용액으로 표지하여 호일로 빛을 차광하여 이를 1시간정도 방치하였다.In a medium containing penicilin / streptomycin in 5% RPMI medium, 10 4 cells were dispensed in a 6 well culture dish containing a slim cover glass and incubated at 37 ° C. for 24 hours, in Preparation Example 1 of the present invention. The reaction was observed by adding the prepared pharmaceutical composition to 50 ㎍ / ml, and after removing the waste solution, the cells were washed with PBS once, and the cells were fixed with metanol on the cells, and then washed with PBS and then run three times After blocking with 0.2% BSA (bovine serum albumin), the first antibody, Anti-mouse-CD4 + / CD8 +, was labeled with a second antibody, anti-mouse-conjugated FITC solution, and then shaded with foil. It was left.

이를 형광현미경에서 관찰하였으며, 그 결과는 도 9에서 보는 바와 같이 정상군은 약한 반응을 보이나 대조군은 강한 녹색형광의 수가 증가하는 경향을 보인 반면 실험군에서는 형광 발현이 크게 감소하고 수적으로 대조군에 비해 많이 감소하는 경향을 나타냄을 알 수 있다.This was observed under a fluorescence microscope. As a result, as shown in FIG. 9, the normal group showed a weak response, but the control group showed a tendency to increase the number of strong green fluorescence, whereas the fluorescence expression was significantly decreased in the experimental group and was much higher than the control group. It can be seen that there is a tendency to decrease.

이하 본 발명에 따른 생약추출물을 직접 정제, 과립제 또는 연질캅셀로 제조할 수 있으며, 또한 차 및 음료등 각종 식품에 첨가하여 알레르기성 질환 증상의 개선기능을 갖도록 하는 기능성 식품을 제조할 수 있다.The herbal extracts according to the present invention can be prepared directly by tablets, granules or soft capsules, and can be added to various foods such as tea and beverages to produce functional foods to have an allergic disease symptom.

실시예 1> 음료의 제조Example 1 Preparation of Beverages

제조예 1에서 제조한 생약추출물 분말 20중량%, 비타민B1염산염 0.00075중량%, 비타민B2인산에스테르나트륨 0.00075중량%, 비타민B6염산염 0.00045중량%, 엽산 0.00005중량%, 니코틴산아미드 0.003중량%, 구연산 0.095중량%, 당류 25.3중량% 및 정제수 54.6중량%를 혼합하여 여과하는 단계와 이들 혼합물을 90℃이상에서 20초간 살균하여 충전한 후 85℃에서 30분간 살균하여 음료를 제조하였다.20% by weight of the herbal extract powder prepared in Preparation Example 1, 0.00075% by weight of vitamin B 1 hydrochloride, 0.00075% by weight of sodium vitamin B 2 phosphate, 0.00045% by weight of vitamin B 6 hydrochloride, 0.00005% by weight of folic acid, 0.003% by weight of nicotinamide, The mixture was filtered by mixing 0.095% by weight citric acid, 25.3% by weight sugar and 54.6% by weight purified water, and the mixture was sterilized and filled for 20 seconds at 90 ° C or higher, and then sterilized for 30 minutes at 85 ° C.

실시예 2> 정제의 제조Example 2 Preparation of Tablets

실시예 1에 의하여 제조된 분말 500mg, 유당 100mg, 전분 100mg을 혼합하고 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.500 mg of powder prepared in Example 1, 100 mg of lactose and 100 mg of starch were mixed and tableted according to a conventional method for preparing tablets.

실시예 3> 과립제의 제조Example 3 Preparation of Granules

제조예 2에서 제조한 생약추출물 분말 35중량%, 비타민C 0.3중량%, 포도당 28중량%, 덱스트린 28중량%, 70%에탄올 8.7중량%를 함께 반죽하고 과립제조기를 통과시켜 과립 60mesh의 과립을 제조하였다.The crude drug extract powder prepared in Preparation Example 2, 35% by weight of vitamin C, 0.3% by weight of glucose, 28% by weight of glucose, 28% by weight of dextrin, 8.7% by weight of 70% ethanol were kneaded together and passed through a granulation machine to prepare granules of 60mesh granules. It was.

실시예 4> 캡슐제의 제조Example 4 Preparation of Capsules

실시예 1에 의하여 제조된 물추출물 500mg, 유당 50mg, 전분 50mg, 탈크 2mg을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충진하여 캡슐제를 제조하였다.500 mg of water extract prepared by Example 1, 50 mg of lactose, 50 mg of starch, 2 mg of talc were mixed and the capsules were prepared by filling gelatin capsules according to a conventional method for preparing capsules.

이상에서 설명한 바와 같이 본 발명은 의이인, 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려의 생약을 주성분으로 함유하는 알레르기성 질환 증상을 개선할 수 있는 기능성 식품을 제공하며, 본 발명에 따른 알레르기성 질환 증상의 개선활성 기능을 갖는 기능성 식품은 원인과 체질을 불문하고 사용할 수 있으며, 장기간 계속 사용하더라도 소화장애, 어지러움증 및 속쓰림 등의 부작용이 없는 특징을 갖는 발명이다.As described above, the present invention contains herbal medicines of Euiin, baekbaekpi, Eoseongcho, Gilgyeong, rawjihwang, gold and silver, three hundredth, ginger, dermis, baekchul, creation, Astragalus, licorice, peppermint, red pepper, green onion, jujube and medicinal herbs as main ingredients. Provides a functional food that can improve the symptoms of allergic diseases, functional foods having an active function to improve the symptoms of allergic diseases according to the present invention can be used regardless of the cause and constitution, digestive disorders, dizziness, even if used continuously for a long time And it is an invention having the characteristic that there is no side effect, such as heartburn.

도 1은 본 발명에 따른 생약조성물에 대한 과산화지질(過酸化脂質)생성 억제작용 평가를 나타낸 그래프,1 is a graph showing the evaluation of the inhibitory action of lipid peroxide (過 酸化 脂質) production on the herbal composition according to the present invention,

도 2는 본 발명에 따른 생약조성물에 대한 쥐 경구투여에서의 항(抗)알레르기 작용(PCA법) 평가를 나타낸 그래프,2 is a graph showing the evaluation of antiallergic action (PCA method) in oral administration of rats to the herbal composition according to the present invention,

도 3은 본 발명에 따른 생약조성물에 대한 5-리포키시게나제 저해작용 평가를 나타낸 그래프,Figure 3 is a graph showing the evaluation of 5-lipokishinase inhibitory effect on the herbal composition according to the present invention,

도 4는 본 발명에 따른 생약조성물에 대한 항(抗)히스타민 작용 평가를 나타낸 그래프,Figure 4 is a graph showing the evaluation of anti-histamine action on the herbal composition according to the present invention,

도 5는 본 발명에 따른 생약조성물에 대한 트라이나이트로페닐(TNP)의 특이적 면역조정능력반응 실험을 나타낸 그래프,5 is a graph showing a specific immunomodulatory capacity test of trinitrophenyl (TNP) for the herbal composition according to the present invention,

도 6은 본 발명에 따른 생약조성물에 대한 호산구 증가 억제 실험을 나타낸 그래프,6 is a graph showing the eosinophil increase inhibition experiment for the herbal composition according to the present invention,

도 7은 본 발명에 따른 생약조성물에 대한 비염 유도쥐내 폐세기관지 임파구수를 나타낸 그래프,Figure 7 is a graph showing the number of lymphatic bronchial lymphocytes in the rhinitis induced rats for herbal composition according to the present invention,

도 8은 본 발명에 따른 생약조성물에 대한 폐세기관지내 임파구의 tryphan blue 염색을 형태학적으로 나타낸 현미경 확대도(×200),FIG. 8 is a microscopic magnification (× 200) of morphologically showing tryphan blue staining of lymphocytes in pulmonary bronchus for a herbal composition according to the present invention; FIG.

도 9는 본 발명에 따른 생약조성물에 대한 폐세기관지내 면역세포화학분석법으로 나타낸 형광현미경 확대도(×200)이다.9 is an enlarged fluorescence microscope (× 200) shown by the immunocytochemical analysis of pulmonary bronchioles for herbal compositions according to the present invention.

Claims (4)

의이인에 대하여 상백피, 어성초, 길경, 생지황, 금은화, 삼백초, 생강, 진피, 백출, 창출, 황기, 감초, 박하, 적작, 파, 대추 및 모려 각각의 중량비가 1 : 0.7~1 : 0.7~1 : 0.7~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 0.1~1 : 1~10 : 0.1~1 : 0.01~0.1 배합되어 제조된 생약추출물을 유효성분으로 함유하는 알레르기성 질환 증상의 개선용 식품첨가제.For Euiin, the weight ratio of Sangbaekpi, Eoseongcho, Gilgyeong, Saenghwanghwang, Geumhwa, Sambaekcho, Ginger, Dermis, Baekchul, Creation, Astragalus, Licorice, Peppermint, Red Rice, Green onion, Jujube and Moji 1: 0.7 ~ 1: 0.7 ~ 1: 0.7 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 0.1 ~ 1: 1 ~ 10: 0.1 ~ 1: 0.01 ~ 0.1 Food additive for improving allergic disease symptom containing herbal extract prepared as an active ingredient. 상기 제1항에 기재된 식품첨가제를 총 중량 대비 5~80 중량 % 함유함을 특징으로 하는 알레르기성 질환 증상의 개선활성을 갖는 기능성 식품Functional food having an allergic disease symptom improving activity, comprising 5 to 80% by weight of the food additive according to claim 1 relative to the total weight 제 2 항에 있어서, 상기 식품은 정제, 과립제, 연질캅셀제 또는 액제 제형 중에서 선택됨을 특징으로 알레르기성 질환 증상의 개선활성을 갖는 기능성 식품According to claim 2, wherein the food is a functional food having an allergic disease symptom improving activity, characterized in that selected from tablets, granules, soft capsules or liquid formulations 제 2 항에 있어서, 상기 기능성 식품은 음료 또는 다류 임을 특징으로 하는 알레르기성 질환 증상의 개선활성을 갖는 기능성 식품.According to claim 2, wherein the functional food is a functional food having an allergic disease symptoms improvement activity, characterized in that the beverage or tea.
KR10-2003-0068445A 2002-10-02 2003-10-01 A functional food Containing herbes composition for allergy disease treatment KR100504767B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020020060006A KR20030007243A (en) 2002-10-02 2002-10-02 Phamaceutical composition comprising COCICIS SEMEN, MORI COTEX RADICIS, HOUTTUYNIA CORDATA, PLATYCODI RADIX, REHMANNIAE RADIX, LONICERAE FLOS, SAURURUS CHINESIS LOUR BAIL, ZINGIBER OFFICINALE ROSCOE, PAEONIAE RADIX RUBRA as main ingredients
KR1020020060006 2002-10-02
KR1020020068267A KR20020089275A (en) 2002-11-05 2002-11-05 Phamaceutical use for treating allergic rhinitis and atopic dermatitis comprising as main ingredients COCICIS SEMEN, MORI COTEX RADICIS, HOUTTUYNIA CORDATA, PLATYCODI RADIX, REHMANNIAE RADIX, LONICERAE FLOS pharmaceutical preparations containing them
KR1020020068267 2002-11-05

Publications (2)

Publication Number Publication Date
KR20040030370A KR20040030370A (en) 2004-04-09
KR100504767B1 true KR100504767B1 (en) 2005-07-29

Family

ID=37331317

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2003-0068446A KR100527834B1 (en) 2002-10-02 2003-10-01 Oriental herb composition for allergy disease treatment
KR10-2003-0068445A KR100504767B1 (en) 2002-10-02 2003-10-01 A functional food Containing herbes composition for allergy disease treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR10-2003-0068446A KR100527834B1 (en) 2002-10-02 2003-10-01 Oriental herb composition for allergy disease treatment

Country Status (1)

Country Link
KR (2) KR100527834B1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050079256A (en) * 2004-02-05 2005-08-10 주식회사 리젠 바이오텍 Composition for preventing and treating allergic diseases comprising extracts of houttuynia cordata and rubus coreanus
WO2006007538A2 (en) * 2004-07-01 2006-01-19 Baek Sung H Composition and method for the treatment of asthma symptoms
KR100715356B1 (en) * 2005-03-03 2007-05-04 서두석 Antioxidant and Anti-Allergic featured food for promoting health
KR100675618B1 (en) * 2005-04-25 2007-01-30 영남대학교 산학협력단 Composition comprising the extract of Saururus chinensis for the prevention or treatment of asthma or allegic disease
KR100720671B1 (en) * 2006-02-23 2007-05-21 경희대학교 산학협력단 The composition comprising extracts of gentiana scabra, citrus unshiu marcor and coptis chinensis for treatment of type iv allergy and an inflammation
KR100794445B1 (en) * 2006-12-05 2008-01-16 남종현 Functional food composition for treating allergy, natural tee using the same and the manufacturing method thereof
KR100841408B1 (en) * 2007-06-12 2008-06-25 성균관대학교산학협력단 Pharmaceutical composition for sepsis and septic shock comprising lonicera japonica thunberg extract as an effective component
KR100878353B1 (en) * 2008-03-06 2009-01-14 (주)유니허브 A composition of make-up material and the cosmetic utilizing thereof
KR100931351B1 (en) * 2009-10-23 2009-12-11 (주)아모레퍼시픽 Skin compositions for exteral application, containing plant extracts
KR100931350B1 (en) * 2009-10-23 2009-12-11 (주)아모레퍼시픽 Skin compositions for exteral application, containing plant extracts
KR100990195B1 (en) * 2010-01-20 2010-10-29 (주)엘큐어 Allergic or atopic dermatitis-alleviating natural cosmetic composition
KR101372324B1 (en) * 2012-02-09 2014-03-13 동국대학교 경주캠퍼스 산학협력단 Pharmaceutical composition of controlled release complex formulation comprising pseudoephedrine and traditional herbal medicine for the treatment of allergic rhinitis
CN102716331B (en) * 2012-06-27 2014-03-05 陈慧婷 Prepared rehmannia root traditional Chinese medicine preparation for treating vertigo and preparation method of preparation
CN104922484B (en) * 2015-06-12 2018-03-27 公安县中医医院 A kind of Chinese medicinal pill for treating vertigo
US20210338759A1 (en) * 2018-05-28 2021-11-04 Korea Institute Of Science And Technology Composition for preventing or treating allergic diseases containing mixed extract of two or more among asiasarum root, platycodon root, and cinnamomi ramulus as active ingredients
KR20220161744A (en) * 2021-05-31 2022-12-07 (주)보인바이오컨버젼스 Composition for improving respiratory diseases containing essential oil extract derived from natural products as an active ingredient
KR102644323B1 (en) * 2022-11-16 2024-03-06 김태우 Method for producing functional food composition for improving joint health

Also Published As

Publication number Publication date
KR20040030371A (en) 2004-04-09
KR20040030370A (en) 2004-04-09
KR100527834B1 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
KR100504767B1 (en) A functional food Containing herbes composition for allergy disease treatment
RU2319500C2 (en) Compositions for preventing or treating pollinosis, allergic rhinitis, atopic dermatitis, asthma or urticaria
CN111617231B (en) Uric acid-reducing and gout-resisting composition as well as preparation method and application thereof
ES2394316T3 (en) Pharmaceutical compositions of Carapa Guianensis.
KR100414453B1 (en) Artemisia asiatica extract as agent for treatment of inflammatory bowel disease
KR101000951B1 (en) Dicoumarol-removed-extract of artemisia, preparation and pharmaceutical compositions thereof
CN109078134A (en) It is a kind of that not only there is Chinese medicine composition and preparation method thereof that is anti-oxidant but also can reduce gout patients serum Uric Acid Concentration
US11179430B2 (en) Extracts from mother-of-thyme and the use i&#39;hereof
CN103877438A (en) Traditional Chinese medicine preparation for treating gout and production method thereof
KR100720671B1 (en) The composition comprising extracts of gentiana scabra, citrus unshiu marcor and coptis chinensis for treatment of type iv allergy and an inflammation
CN101152223B (en) Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease
CN103933154B (en) A kind of Chinese medicine composition treating goat and preparation method thereof
CN103705772B (en) Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof
KR101113593B1 (en) A pharmaceutical comprising the extract of red panax ginseng, gastrodia rhizoma and polygoni multiflori radix for treating or preventing erectile dysfunction
CN102274428B (en) Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof
KR102506493B1 (en) Composition for preventing or treating edema comprising Prasiola japonica extract or fraction thereof as active ingredient
US6444236B1 (en) Compositon containing medicinal herbs and young antlers of cornu cervi
KR20020007806A (en) Composition comprising extract of medicinal herbs for preventing and curing allergy and/or asthma
CN115040576B (en) Pharmaceutical composition for treating acute pancreatitis
KR20230149568A (en) Composition for preventing, improving or treating allergic respiratory disease comprising Alpinia officinarum extract as effective component
CN100522158C (en) Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis
KR100761938B1 (en) Pharmaceutical composition for preventing or treating impotence induced hyperlipidemia and/or hypertension
CN107362236A (en) A kind of composition with auxiliary function for lowering blood pressure and preparation method thereof
KR100758364B1 (en) Pharmaceutical composition for preventing or treating impotence
CN107362288A (en) It is a kind of that there is composition for improving sleep function and preparation method thereof

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120718

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20130715

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20150721

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20160720

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20170721

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20180723

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20190722

Year of fee payment: 15